Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Peer-Reviewed Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Dpp3em1/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Dpp3em1/Cya

Common Name
Dpp3-KO
Product ID
S-KO-17752
Backgroud
C57BL/6JCya
Strain ID
KOCMP-75221-Dpp3-B6J-VB
Status
Research and Development
When using this mouse strain in a publication, please cite “Dpp3-KO Mouse (Catalog S-KO-17752) were purchased from Cyagen.”
KO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
KO Models
Basic Information
Strain Name
Dpp3-KO
Strain ID
KOCMP-75221-Dpp3-B6J-VB
Gene Name
Dpp3
Product ID
S-KO-17752
Gene Alias
DPP III, 4930533O14Rik
Background
C57BL/6JCya
NCBI ID
75221 (Mouse)
Modification
Conventional knockout
Chromosome
Chr 19 (Mouse)
Phenotype
MGI:1922471
Datasheet
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000025851
NCBI Transcript ID
NM_133803
Target Region
Exon 6
Size of Effective Region
~0.1 kb
Overview of Gene Research
Dpp3, also known as dipeptidyl peptidase 3, is the first zinc-dependent peptidase among DPPs. It has a unique HEXXGH catalytic sequence and is mainly located in the cytoplasm, associated with the degradation of oligopeptides with 4-10 amino acid residues. It participates in multiple cellular activities and pathophysiological mechanisms, including interacting with the renin-angiotensin system to regulate blood pressure, and is involved in pain signaling, inflammation, and oxidative stress [1].

In cardiovascular diseases, Dpp3 is used as a biomarker for poor prognosis in patients. For example, in cardiogenic shock patients, the plasma concentration of Dpp3 is closely related to mortality, and higher levels in ventilated patients may predict disease progression [1,6]. In cancer, Dpp3 is upregulated in breast, esophageal, and colorectal cancers. In breast cancer, it promotes tumorigenesis by stabilizing FASN and promoting lipid synthesis [2]. In esophageal carcinoma, its depletion reduces cell proliferation, migration, and tumor growth in a xenograft model [3]. In colorectal cancer, downregulation of Dpp3 inhibits cell proliferation, migration, and promotes apoptosis, and Dpp3 may act through targeting CDK1 [4]. In esophageal squamous cell carcinoma, knockdown of Dpp3 leads to reduced proliferation, increased apoptosis, and inhibited migration, along with down-regulation of the NRF2 pathway and increased sensitivity to oxidative stress and chemotherapy [5].

In conclusion, Dpp3 plays a significant role in cardiovascular diseases as a biomarker and potentially as a therapeutic target. In cancer, it promotes tumor development and progression in multiple types of malignancies. The study of Dpp3 in gene-knockout or conditional-knockout models, although not directly mentioned in the references in terms of these models, would further clarify its exact mechanisms in these biological processes and diseases, providing a better understanding of its biological functions and potential for treatment strategies.

References:
1. Ye, Peng, Duan, Wei, Leng, Yue-Qi, Tan, Xing, Wang, Wei-Zhong. 2022. DPP3: From biomarker to therapeutic target of cardiovascular diseases. In Frontiers in cardiovascular medicine, 9, 974035. doi:10.3389/fcvm.2022.974035. https://pubmed.ncbi.nlm.nih.gov/36312232/
2. Fu, Xiaoyu, Li, Xu, Wang, Weixing, Li, Juanjuan. . DPP3 promotes breast cancer tumorigenesis by stabilizing FASN and promoting lipid synthesis. In Acta biochimica et biophysica Sinica, 56, 805-818. doi:10.3724/abbs.2024054. https://pubmed.ncbi.nlm.nih.gov/38655619/
3. Liu, Jing-Kun, Abudula, Abulizi, Yang, Hai-Tao, Tulahong, Aisiker, Eli, Maynur. 2022. DPP3 expression promotes cell proliferation and migration in vitro and tumour growth in vivo, which is associated with poor prognosis of oesophageal carcinoma. In Oncology reports, 49, . doi:10.3892/or.2022.8446. https://pubmed.ncbi.nlm.nih.gov/36382663/
4. Tong, Yixin, Huang, Yuan, Zhang, Yuchao, Xia, Zhongsheng, Lai, Dongming. 2021. DPP3/CDK1 contributes to the progression of colorectal cancer through regulating cell proliferation, cell apoptosis, and cell migration. In Cell death & disease, 12, 529. doi:10.1038/s41419-021-03796-4. https://pubmed.ncbi.nlm.nih.gov/34023852/
5. Arora, Mohit, Kumari, Sarita, Kadian, Lokesh, Chopra, Anita, Chauhan, Shyam S. . Involvement of DPP3 in modulating oncological features and oxidative stress response in esophageal squamous cell carcinoma. In Bioscience reports, 43, . doi:10.1042/BSR20222472. https://pubmed.ncbi.nlm.nih.gov/37531267/
6. Innelli, Pasquale, Lopizzo, Teresa, Paternò, Giovanni, Pittella, Giuseppe, Paternoster, Gianluca. 2023. Dipeptidyl Amino-Peptidase 3 (DPP3) as an Early Marker of Severity in a Patient Population with Cardiogenic Shock. In Diagnostics (Basel, Switzerland), 13, . doi:10.3390/diagnostics13071350. https://pubmed.ncbi.nlm.nih.gov/37046568/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research